In February, the Federal Trade Commission settled with pharmaceutical benefits manager (PBM) Express Scripts. The FTC had sued Express Scripts and two other large PBMs under the long dormant Section 5 of the FTC Act, which targets “unfair methods of competition.” The settlement suggests that the FTC may succeed in addressing the convoluted contracts between PBMs, drug manufacturers, health insurers, and employers that drive up drug prices for Americans. It also opens unchartered territory for antitrust enforcement and the limits of Section 5, argue Fiona Scott Morton and Mariah Smith.

In new research, Renuka Diwan, Paul Eliason, Riley League, Ryan C. McDevitt, James W. Roberts, and Jetson Leder-Luis investigate how Medicare’s shift to a competitive bidding system to reduce prices has inadvertently shifted market share to fraudulent suppliers.

Antitrust authorities increasingly assess mergers through the lens of innovation, particularly in research-intensive sectors such as pharmaceuticals. In new research, Carmine Ornaghi and Lorenzo Cassi show how mergers disrupt human capital and reduce innovation in what they call manslaughter acquisitions.

In new research, Martin Schmalz and Jin Xie examine how shareholder preferences influence the United States pharmaceutical industry. They find that generic-drug manufacturers sometimes harm their firms’ own value when doing so benefits shareholder portfolios, who frequently have stakes in competing brand-name firms.

In new research, Grace Fan, Trung Nguyen, and Xi Wu show how improvements in government data transparency and disclosure through the public rollout of the Environmental Protection Agency’s Environmental Justice Screening and Mapping Tool enabled civil society to identify and hold polluters responsible and improve overall environmental justice.

Finbar Curtin and Matthew Burgess’ recent article analyzing the relationship between the climate and economy has been interpreted as a study proving that climate change’s impact on economic growth is weak. Garvin Jabusch argues that this interpretation is wrong. Rather, the article concludes that statistical estimates of this relationship are limited by data and future capital allocation should favor a ‘no-regrets’ approach anchored in observable cost curves and productive capacity.

In new research, Wei Cai, Andrea Prat, and Jiehang Yu evaluate how mergers affect employee satisfaction. They find that acquired firms report a decline in worker satisfaction, primarily revolving around “soft” benefits, such as workplace culture, management quality, and trust.

The competitiveness of the artificial intelligence market at first glance masks how investment arrangements and partnerships between the largest players risks undermining their incentives to compete. Regulators must continue to monitor these arrangements for anticompetitive effects, writes Shishene Jing.